NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this publication

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide Distribution Center
National Institutes of Health
Room B3B07, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 19, No. 38
October 19, 1990
NOTICES

THE NATIONAL CELL CULTURE CENTER ........................................ 1
National Center for Research Resources
Index: RESEARCH RESOURCES

HEALTH AND SAFETY GUIDELINES FOR GRANTEES AND CONTRACTORS .......... 1
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
Index: NATIONAL INSTITUTES OF HEALTH
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION

NOTICES OF AVAILABILITY (RFPs AND RFAs)

DETAILED DRUG EVALUATION OF ANTI-AIDS AGENTS (RFP) ..................... 2
National Cancer Institute
Index: CANCER

REFERENCE LABORATORY FOR NONTUBERCULOUS MYCOBACTERIA ISOLATED
FROM AIDS PATIENTS (RFP) .................................................. 3
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES

EVALUATION OF AIDS THERAPIES IN ANIMAL RETROVIRAL MODELS SIV (RFP) .... 4
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES

TECHNICAL SUPPORT SERVICES FOR THE NIDDK EPIDEMIOLOGY COMMITTEE (RFP) .... 4
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES

EVALUATION OF PHARMACOKINETICS OF AIDS THERAPIES IN NON-HUMAN
PRIMATES (RFP) .............................................................. 5
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES

MECHANISMS OF TOXICITY OF THERAPEUTIC AGENTS USED FOR HIV AND
AIDS-RELATED DISEASES (RFA ES-91-01) .................................... 6
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES

ONGOING PROGRAM ANNOUNCEMENTS

FOGARTY SENIOR INTERNATIONAL FELLOWSHIPS FOR U.S. SCIENTISTS (PA-91-02) ..... 7
Fogarty International Center
Index: FOGARTY INTERNATIONAL CENTER

COGNITION AND MENTAL HEALTH: BEHAVIORAL AND NEURAL APPROACHES (PA-91-03) ... 10
National Institute of Mental Health
Index: MENTAL HEALTH

The National Cell Culture Center is a resource available to researchers throughout the country. The Center will provide biomedical investigators with customized services for large quantity production of animal cells and secreted proteins. The goal is to facilitate basic research and ease the burden placed on scientists by large-scale cell production. The Center, directed by Dr. Mark Hirschel, provides cells in suspension and monolayer cultures in quantities ranging from 25 to 150 liters.

In addition, cell-secreted products such as monoclonal antibodies, are available in quantities of 1 to 100 grams.

An application form, obtained from the Cell Culture Center, must contain a description of the relevant research project. Following approval of the application by the Cell Culture Center's Scientific Advisory Board, the cell line is sent to the Center, and grown to the requested amount. Researchers are charged only for the consumable materials and a portion of the labor costs required for each project. Application forms and inquiries should be directed to:

Mark Hirschel, Ph.D.
Director
National Cell Culture Center
Endotronics, Inc.
Minneapolis, MN 55433
Telephone: 1-800-325-1112

The Cell Culture Center is supported by a cooperative agreement award from the National Center for Research Resources, NIH.

Health and Safety Guidelines for Grantees and Contractors

This notice is a republication, with minor modifications, of an April 1989 issuance on this subject. It is being reissued to emphasize its continuing importance.

Organizations receiving grant or contract awards are responsible for protecting their personnel from hazardous conditions. The Government is not legally liable for accidents, illnesses, or claims arising out of research performed under its awards, but the National Institutes of Health (NIH) and the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) are nonetheless aware that a variety of hazards threaten the safety and health of both laboratory and clinical research personnel. Accordingly, the guidelines that follow are designed to (1) identify potential hazards, (2) advise awardee organizations and investigators of certain standards that should be considered in order to address particular health and/or safety concerns, and (3) emphasize that concerns about potentially hazardous conditions could result in grant or contract funding delays until those concerns have been resolved to the satisfaction of the awarding component.

1. Sources of potential danger to research personnel include the following classes of hazard:
   a. Biohazards (e.g., Human Immunodeficiency Virus, HIV; other infectious agents; oncogenic viruses).
   b. Chemical hazards (e.g., carcinogens; chemotherapeutic agents; other toxic chemicals; flammable or explosive materials).
   c. Radioactive materials.

2. The following guidelines and standards contain information designed to assist grantees and contractors in providing a safe work environment for research personnel. Therefore, depending upon the particular safety hazard at
issue, grantees and contractors are expected to consult these guidelines. Single copies may be obtained from:

Division of Safety
Office of Research Services
National Institutes of Health
Building, 31, Room 1C02
Bethesda, MD 20892


d. NIH Guidelines for the Laboratory Use of Chemical Carcinogens, NIH Publication No. 81-2385.

The following materials are also recommended and may be purchased from:

National Academy Press
2102 Constitution Avenue, N.W.
Washington, D.C. 20418

A. Prudent Practices for Handling Hazardous Chemicals in the Laboratory. Price $19.95

B. Prudent Practices for the Disposal of Chemicals from the Laboratory. Price $19.95

C. Biosafety in the Laboratory: Prudent Practices for Handling and Disposal of Infectious Materials. Price $29.95

3. Grant applications and contract proposals posing special hazards typically are identified during the initial review process, but such concerns can formally be expressed by agency staff or consultants at any time prior to award. Regardless of the timing of the described concern, grant or contract funding could be delayed until the matter has been resolved to the satisfaction of the awarding component.

Special hazards that are identified after an award is made may lead to suspension of work under the grant or contract pending corrective action by the awardee. (See 45 CFR 74, Subpart M, concerning grant suspension and 48 CFR 12.5 concerning contract "stop work" orders.)

Grantee and contractor organizations are not required to submit documented assurance of their specific attention to the guidelines and standards identified in section 2 of this notice. However, where dictated by the circumstances, grantees and contractors should be able to provide evidence that pertinent health and safety standards have been considered and, where necessary, have been put in practice. Such evidence may be requested by appropriate NIH and ADAMHA staff; for example, during a site visit.

NOTICES OF AVAILABILITY (RFPs AND RFAs)

DETAILED DRUG EVALUATION OF ANTI-AIDS AGENTS

RFP AVAILABLE: NCI-CM-17525-27

P.T. 34; K.W. 0715008, 0740012, 0760035, 0710100

National Cancer Institute

The Developmental Therapeutics Program (DTP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), is seeking contractors to conduct a
number of specialized in vitro and in vivo studies on compounds that are known to inhibit the growth and/or cytopathic effects of human immunodeficiency virus (HIV) and other similar retroviruses. Studies will be conducted to assess the antiviral efficacy of potential anti-HIV agents newly identified by the DTP anti-HIV in vitro screen. Emphasis will be placed on experiments to determine the influence of dose, exposure time, and route of administration on the antiviral activity of new agents in small animal retroviral model(s), and to compare the in vivo effects with the in vitro effects obtained with the same virus. Additional studies may include those to evaluate compound tolerance in small animals, compare efficacies of related compounds and determine the synergistic potential of compounds in combination. Information gathered by the contract will be used to help in the determination of the most appropriate candidate compound(s) for development and to devise and recommend treatment strategies for clinical trial. In order to protect the laboratory environment and safety of personnel, any offeror proposing to conduct studies using HIV (or other retroviruses with similar pathogenic potential in man) must utilize facilities meeting Biosafety Level 3 criteria. Compounds to be studied will be selected and assigned by the Government. As compounds of a commercially confidential nature (discreet) may be evaluated, pharmaceutical and chemical firms will be excluded from the competition. Also, since structural formulae of discreet materials may be provided by the Government on occasion, the organization must be willing to sign a confidentiality of information statement.

The Principal Investigator (PI) should have a M.D., D.V.M., or Ph.D. in one of the relevant biological sciences (or equivalent experience), should have managerial experience, and experience either in managing an in vivo screening program utilizing small animals or in evaluating the efficacy, toxicity, or mechanism of antiviral agents. The PI should devote approximately 25 percent of his/her time to the project. It is anticipated that one incrementally funded contract will be awarded for a period of three (3) years. Each increment will be for a period of one year. The contract will be written on a "level of effort" basis specifying that the contractor is to furnish approximately 31,500 direct labor hours over three years (10,500 labor hours per year).

RFP No. NC1-CM-17525-27 will be available on or about October 31, 1990. Responses will be due December 17, 1990. Copies of the RFP may be obtained by sending a written request to:

Mr. Johnny Jordan  
Contract Specialist  
Treatment Contracts Section  
Research Contracts Branch  
National Cancer Institute  
Executive Plaza South, Room 603  
Bethesda, MD 20892

This project is a recompetition of the work being done under contract number N01-CM-87274 Southern Research Institute, Alabama. No collect calls will be accepted.

REFERENCE LABORATORY FOR NONTUBERCULOUS MYCOBACTERIA ISOLATED FROM AIDS PATIENTS

RFP AVAILABLE: RFP-NIH-NIAID-DAIDS-91-12

P.T. 34; K.W. 0715008, 0755018, 0755010

National Institute of Allergy and Infectious Diseases

The Treatment Research Program, Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, has a need for organizations having the capability and facilities to assemble and maintain a scientific database on the results of the testing of nontuberculous mycobacteria originating from patient materials that are infected with HIV; perform quantitative cultures and standardized in vitro antibiotic susceptibility testing; and, perform classification of isolates for serotyping, prepare necessary reagents, and maintain collections of verified serotypes.

This is an announcement of an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-DAIDS-91-12 was issued on October 4, 1990. Closing date for receipt of proposals is tentatively set for November 19, 1990.

The announcement of availability of this RFP appeared in the Commerce Business Daily on September 17, 1990. The NIH regrets
the delay in the publication of this announcement in the NIH Guide for Grants and Contracts.

To receive a copy of the RFP, please supply this office with two self-addressed mailing labels. All responsible sources may submit a proposal that will be considered.

Request for the RFP shall be directed in writing to:

Mr. Phillip Hastings Contract Management Branch Control Data Corp. Bldg., Rm. 222P 6003 Executive Boulevard National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Telephone: (301) 496-0194

This advertisement does not commit the Government to make awards.

EVALUATION OF AIDS THERAPIES IN ANIMAL RETROVIRAL MODELS SIV

RFP AVAILABLE: RFP-NIH-NIAID-DAIDS-91-09

P.T. 34; K.W. 0715008, 0740012, 0710100

National Institute of Allergy and Infectious Diseases

The Basic Research and Development Program of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH has a requirement for investigations of anti-retroviral therapies against SIV using both in vitro and in vivo non-human Primate Animal Model Test Systems. A companion RFP (RFP-NIH-NIAID-DAIDS-91-10) is available to provide pharmacokinetics studies to support and complement the current initiative. These model systems will be used by the Division of AIDS of the NIAID in its efforts to develop anti-retroviral drugs and therapies, and to better understand how therapies may be used to treat or prevent HIV infection and associated disease in humans. Because of the similarities between SIV and HIV, and the physiological closeness of non-human primates to humans, these models are important in helping determine priorities for therapies to enter clinical trials. The model systems to be investigated should reflect the clinical, immunological, and virological aspects of HIV infections in humans. It is anticipated that this information will permit the improved understanding of treatment of HIV infections in humans. This announcement is a recompetition and expansion of a previous program; multiple awards are anticipated. The issuance of the RFP will be on or about October 11, 1990, and proposals will be due by COB on or about January 8, 1991.

Request for the RFP shall be directed in writing to:

Ms. Mary Anne Glitz
Contract Management Branch
Control Data Corp. Bldg., Rm. 222P
6003 Executive Boulevard
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-1642

To receive a copy of the RFP, please supply this office with two self-addressed mailing labels. All responsible sources may submit a proposal which will be considered.

This advertisement does not commit the Government to make awards.

TECHNICAL SUPPORT SERVICES FOR THE NIDDK EPIDEMIOLOGY COMMITTEE

RFP AVAILABLE: RFP-NIH-NIDDK-91-1

P.T. 34; K.W. 0785055, 0755018, 1010013

National Institute of Diabetes and Digestive and Kidney Diseases

THIS ACQUISITION IS 100 PERCENT SMALL BUSINESS SET-ASIDE

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking an organization to provide technical support services for the NIDDK Epidemiology Committee. These services shall include the performance of tasks that involve the following: data management and data processing support in analysis of complex biomedical data files; epidemiologic and biostatistical...
consultation in assessment and analysis of data relating to the various diseases under the purview of the NIDDK; and preparation of technical reports on these analyses.

This acquisition is under a 100 percent Small Business Set-Aside.

This Request for Proposals, RFP No. NIH-NIDDK-91-1, will be issued on or about October 22, 1990, with a closing date December 7, 1990. To receive a copy of this RFP, please supply this office with two self-addressed mailing labels and cite the RFP number referenced above. Requests must be in writing and addressed to:

Shirley A. Shores  
Contracts Management Branch  
National Institute of Diabetes and Digestive and Kidney Diseases  
Westwood Building, Room 602  
Bethesda, MD 20892

This advertisement does not commit the Government to make an award.

EVALUATION OF PHARMACOKINETICS OF AIDS THERAPIES IN NON-HUMAN PRIMATES

RFP AVAILABLE: RFP-NIH-NIAIDS-DAIDS-91-10  
P.T. 34; K.W. 0715008, 0710100

National Institute of Allergy and Infectious Diseases

The Basic Research and Development Program of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH, has a requirement for the evaluation of pharmacokinetics of AIDS therapies in non-human primates. In addition, this initiative is intended to provide pharmacokinetics support to other contracts using non-human primates to test efficacy of anti-retroviral therapies. Many of the drugs to be evaluated are provided from outside sources; thus, the contractor must be bound by the same terms of confidentiality as the Division of AIDS of the NIAID in its efforts to develop antiretroviral drugs and therapies; specifically, information will be used in the design of trials in animal models and, where appropriate, in the design of clinical trials. Because of the similarities between the physiology of non-human primates to humans, these models are important in helping determine priorities for therapies to enter clinical trials. It is anticipated that this information will permit the improved understanding of treatment of HIV infections in humans. This announcement is a new solicitation; a single award is anticipated. The issuance of the RFP will be on or about October 11, 1990, and proposals will be due by COB on or about January 8, 1991. The NIAID-sponsored project will take approximately 5 years to complete. A cost-reimbursement contract is anticipated.

Request for the RFP shall be directed in writing to:

Ms. Mary Anne Glitz  
Contract Management Branch  
Control Data Corp. Bldg., Rm. 222P  
6003 Executive Boulevard  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Bethesda, MD 20892  
Telephone: (301) 496-1642

To receive a copy of the RFP, please supply this office with two self-addressed mailing labels. All responsible sources may submit a proposal which will be considered.

This advertisement does not commit the Government to make awards.
MECHANISMS OF TOXICITY OF THERAPEUTIC AGENTS USED FOR HIV AND AIDS-RELATED DISEASES

RFA AVAILABLE: ES-91-01

P.T. 34; K.W. 0715008, 0740012, 1007009

National Institute of Environmental Health Sciences

Letter of Intent Receipt Date: December 15, 1990
Application Receipt Date: January 15, 1991

PURPOSE

The National Institute of Environmental Health Sciences (NIEHS) announces the availability of new funds to support research efforts aimed at understanding the mechanisms responsible for the toxicologic side effects of therapeutic agents utilized in the treatment of HIV and HIV-related infections.

RESEARCH GOALS AND SCOPE

This Request for Applications (RFA) is issued to foster research toward understanding the toxicological effects, as related to their mechanisms of action, of those agents showing promise for the treatment of the AIDS virus and AIDS-related infections. The limited number of effective therapies for HIV available requires that drugs with known side effects continue to be used in humans. Hence, because of their toxicity, the use of these drugs in humans is often limited. Therefore, the major research emphasis is directed toward understanding the toxicological mechanisms of action for these drugs. It is hoped that by understanding the mechanisms of action, alternative therapies may be developed.

Drugs of interest include, but are not limited to, the nucleoside analogs. Mechanistic studies on the toxicity resulting from combining therapeutic compounds as well as studies on therapeutic agents for opportunistic infections and other AIDS-related diseases are also encouraged. The mechanisms of toxicity of the following examples are of particular interest:

- AZT-induced anemia, granulocytopenia, and/or myopathy.
- ddI-induced pancreatitis and peripheral neuropathy.
- ddC-induced peripheral neuropathy.
- ddA-induced immune and renal dysfunction. (Although this compound is no longer in use, important new information regarding its mechanism of toxicity could be useful in understanding the toxicological effects of other prospective agents.)
- Certain cytokines and other biologic agents, given in conjunction with the nucleoside analogs, appear to have potential in ameliorating the toxicological effects of the analogs. Unfortunately, little is known about the mechanism of cytokine-induced toxicity. These compounds can be especially toxic to the liver. One particular combination therapy, AZT/alpha-interferon, can result in a myelotoxic condition. The mechanism of action in which this toxic condition is caused by this combination therapy remains to be established.
- Therapeutic agents for treating opportunistic infections in AIDS patients also have known toxicological effects, e.g. pentamidine.

It is realized that promising new therapeutic agents may become available between the time of issuance of this announcement and the deadline for receipt of applications. Consideration may be given to applications looking at the mechanisms of toxicity of such relatively new but very promising compounds.

ELIGIBILITY CRITERIA

It is important to emphasize that this research initiative is targeted for those basic research scientists and research clinicians who are specifically interested in the mechanisms of action of known toxicities. RESEARCH DIRECTED TOWARD THE SCREENING OF NEW COMPOUNDS FOR TOXIC EFFECTS WILL BE CONSIDERED AS NON-RESPONSIVE IN TERMS OF THIS ANNOUNCEMENT AND WILL NOT BE REVIEWED FOR SCIENTIFIC MERIT!
INCLUSION OF MINORITIES AND WOMEN IN STUDY POPULATIONS

It is NIH policy that clinical research findings should be of benefit to all persons at risk of a disease regardless of race or gender. Thus, if patients are involved in any of the studies, the inclusion of women and minorities as members of study populations is required. If they are excluded, reasons for this exclusion must be specified in the application.

MECHANISM OF SUPPORT

The mechanism of support for this activity will be the individual research grant (R01). Support for grants is contingent upon receipt of appropriated funds. It is anticipated that four to six meritorious applications will be funded.

APPLICATION AND REVIEW PROCEDURES

Potential applicants are urged to submit a letter of intent by December 15, 1990. The letter of intent is nonbinding and is not a precondition for an award. The letter should include the name(s) of the principal investigator and principal collaborators along with information regarding which therapeutic agents are to be studied in addition to a brief description of the mechanisms of toxicity to be explored. This should not exceed two pages.

This RFA is a one-time solicitation with a specified deadline of January 15, 1991, for receipt of applications. Applications are to be submitted on form PHS 398 (revised 10/88) which is available in the business or grants and contracts offices at most academic and research institutions.

For the expedited review process, the original and 22 copies are to be sent to the Division of Research Grants, Grant Application Receipt Office, Westwood Building, Room 240, National Institutes of Health, Bethesda, Maryland 20892-4500.

Two additional copies should be forwarded to the program official at NIEHS listed below. The applications will be evaluated for scientific merit by a special review panel assembled by the Review Branch of NIEHS. Review criteria include the significance and originality of the research goals and approaches; feasibility of the research and adequacy of the experimental design; training, experience, research competence, and dedication of the investigator(s); adequacy of available facilities; provision for the humane care of animals; and appropriateness of the requested budget relative to the work proposed. Recommendations of the review panel will be considered by the National Advisory Environmental Health Sciences Council at their June meeting. The earliest award date for successful applications will be July 1, 1991.

INQUIRIES

For a copy of the complete RFA and preapplication consultation, contact:

Dr. Jerry A. Robinson
Program Administrator
Scientific Programs Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-7724

ONGOING PROGRAM ANNOUNCEMENTS

FOGARTY SENIOR INTERNATIONAL FELLOWSHIPS FOR U.S. SCIENTISTS

PA: PA-91-02
P.T. 22, 48; K.W. 0720005, 0710030
Fogarty International Center
Application Receipt Dates: January 10, May 10, September 10

PURPOSE

The Senior International Fellowship Program (SIF) was developed to enable U.S. scientists with more than five years postdoctoral experience to carry out research at foreign institutions for periods of three to twelve months. The
intent is to enhance the exchange of ideas and information in all fields of biomedical research between U.S. and foreign scientists.

Beginning with the January 10 receipt date, the SIF program has been modified to provide: up to three separate visits (minimum three months) to the foreign laboratory within a three-year period after activation, for a maximum of twelve months; an increase in the foreign living allowance to $24,000 per year; and an increase in the institutional allowance to $500 per month. The stipend remains at $15,000 for the year.

BACKGROUND AND OBJECTIVES

The SIF provides opportunities to biomedical, behavioral, or health scientists for study or research at a foreign institution. Prospective applicants must have a clear understanding with the foreign host institution about the goals of the fellowship and the work to be pursued.

The Fogarty International Center (FIC) will not accept any proposal that has as its major feature brief observational visits; attendance at formal training courses; or full-time clinical, technical, or teaching services. Successful applicants, beginning with the January 10, 1991 receipt deadline, are afforded the opportunity to divide their fellowship into as many as three separate terms within a three-year period.

ELIGIBILITY

To be eligible for an SIF, an applicant must:

- Hold a doctoral degree in one of the biomedical, behavioral, or health sciences;
- have 5 years or more postdoctoral experience;
- have had professional experience in one of the biomedical, behavioral, or health sciences for at least 2 of the last 4 years;
- hold a full-time appointment on the staff of an institution, which must be a non-Federal public or private not-for-profit research, clinical, or educational institution;
- be invited by a nonprofit foreign institution;
- be a U.S. citizen or permanent U.S. resident;
- not have received more than one SIF previously; and
- not be employed by the Federal Government.

ELIGIBLE COSTS

SIFs are awarded for a total of 3 to 12 months. The award may be divided into as many as three terms, utilized over a three-year period, with a minimum time of three months for any term. Awardees may receive a maximum stipend of $15,000 per year or $1,250 per month. The level of the stipend depends on the amount of salary provided by the U.S. employer during the tenure of the fellowship. The stipend plus the home institution support cannot exceed the awardee's regular annual salary. No stipend will be provided if the awardee receives salary support from other Federal sources. Awardees also receive a foreign living allowance of $24,000 per year or $2,000 per month. This allowance is not reduced by other support including federal funding. The institution may advance the fellow up to $6,000 of the recommended allowance during the first month the fellowship is activated to assist with relocation expenses. The fellow's round-trip fare, economy class on a U.S. air carrier between the U.S. city and host city abroad, will be provided for each of the approved trips (maximum of 3). No travel allowance is provided for family members. The award will include an institutional allowance of up to $6,000 per year, prorated at $500 per month for each visiting period. The fellow is expected to use these funds to defray costs of research supplies and equipment that are required at the foreign host institution.

REVIEW PROCEDURES AND CRITERIA

The initial review process will be conducted by the Division of Research Grants and the following criteria will enter into the decision to recommend approval or disapproval and will influence the priority score assigned to approved applications:
The merit of the applicant's plans for the time spent at the foreign host institution. The proposal should be relevant to the biomedical research mission of the NIH and the FIC, related to the applicant's ongoing work, and a bridge to its continuation after the fellow returns to his or her home institution. The applicant should plan to take advantage of special features of the foreign host environment that are either unavailable or not readily available in the United States. If more than one visit is planned, each separate visit must be clearly justified.

- qualifications and background of the applicant to undertake the proposed project and the ability to complete it within the time(s) planned at the foreign host institution;
- evidence that the proposed arrangements will provide exchanges on technical or scientific matters that will benefit the fellow and the foreign host; and
- evidence that the proposed fellowship will enhance the applicant's future research career.

Prior to funding, the Fogarty International Center's Advisory Board reviews all applications for programmatic considerations.

**AWARD ACTION**

The FIC notifies applicants of their status approximately 6 months after receipt of their applications. SIFs may be activated any time within 1 year of the issue date on the official award notice.

Applications not funded at the end of the first complete review cycle will be carried forward for two additional review cycles for funding consideration before being automatically withdrawn.

**METHOD OF APPLYING**

Special application kits can be requested directly from the Fogarty International Center only. A prospective applicant must:

- Complete the application forms;
- describe the benefits of the fellowship to both the fellow and the foreign host and to both the applicant's and the host's institution;
- carefully justify the benefits of each visit proposed for this fellowship; and
- obtain a letter of invitation and curriculum vitae from the foreign host. The letter should indicate that an understanding has been reached with regard to the plan proposed by the applicant.

Receipt dates for completed applications are January 10, May 10, and September 10. Applications received too late for one review will be considered at the next review cycle.

**Note:** The Fogarty International Center funds and administers a number of fellowship programs. Some individuals who are eligible for a Senior International Fellowship may also be eligible for one or more of these fellowships; however, candidates can apply for only one fellowship during a single review cycle.

For further information and the required application kit, please contact:

David A. Wolff, Ph.D.
Chief, International Research and Awards Branch
Fogarty International Center
Building 31, Room B2C2
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-1653
Facsimile: (301) 402-0779
The National Institute of Mental Health (NIMH) invites applications, using any of the available research grant mechanisms, from investigators who seek to determine the behavioral principles and brain mechanisms of cognition. These mechanisms will reveal the fundamental behavioral principles and biological mechanisms of cognition, broadly interpreted, including their development, maintenance, and pathology over the lifespan of the organism.

Applications may be submitted by public or private nonprofit or for-profit organizations such as universities, colleges, hospitals, laboratories, research institutions, units of State or local governments, and eligible agencies of the Federal Government. Women and minority investigators are encouraged to apply.

INCLUSION OF MINORITIES IN STUDY POPULATIONS

Applicants are encouraged to give added attention (where feasible and appropriate) to the inclusion of minorities in study populations for research into the etiology of diseases, research in behavioral and social sciences, clinical studies of treatment and treatment outcomes, research on the dynamics of health care and its impact on disease, and appropriate interventions for disease prevention and health promotion. If minorities are not included in a given study, a clear rationale for their exclusion should be provided.

INCLUSION OF WOMEN IN STUDY POPULATIONS

Applicants are encouraged to consider the inclusion of women in the study populations for all clinical research efforts. Exceptions would be studies of diseases that exclusively affect males or where involvement of pregnant women may expose the fetus to undue risks. Gender differences should be noted and evaluated. If women are not to be included, a clear rationale should be provided for their exclusion. In order to provide more precise information to the treatment community, it is recommended that publications resulting from research in which the study population was limited to one sex for any reason other than the disease or condition studied exclusively affects that sex, should state, in the abstract summary, the gender of the population studied, e.g., "male patients," "male volunteers," "female patients," or "female volunteers."

Applicants may request support for up to 5 years (renewable for subsequent periods). Annual awards will be made, subject to continued availability of funds and progress achieved. Applications will be accepted and reviewed according to the regular NIMH review schedule.

Additional information concerning this announcement may be obtained from:

Richard Nakamura, Ph.D.
Room 11-105
Telephone: (301) 443-3948

or

Rodney Cocking, Ph.D.
Room 11C-10
Telephone: (301) 443-3942

The address for both of the above is:

Basic Behavioral and Cognitive Science Research Branch
Division of Basic Brain and Behavioral Sciences
National Institute of Mental Health
5600 Fishers Lane
Rockville, MD 20857